Q-omics provides the consensus-scored RN7SKP18 profile across patient tissues and cancer cell-line models. RN7SKP18 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RN7SKP18 is differentially expressed in 2, with the highest sampling consensus in LUAD. Additionally, RN7SKP18 RNA expression shows 12,061 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, LUAD, and LSCC as cancer lineages where RN7SKP18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SKP18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SKP18 survival associations across molecular data types. RN7SKP18 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SKP18 RNA expression–survival associations across cancer types. High RN7SKP18 expression shows unfavorable associations in KIRC, BLCA, ACC, LUSC and GBM, but favorable associations in OV. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RN7SKP18 RNA expression.
This table summarizes RN7SKP18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SKP18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SKP18 shows lower tumor expression in LUAD and LUSC. The LUAD box plot shows higher RN7SKP18 RNA expression in normal versus tumor tissue (log2 FC = −1.057, t-test p < 0.001).
This table shows molecular features associated with RN7SKP18 in patient tissues and cancer cell lines. In patient samples, RN7SKP18 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
